What is it used for?
PULMOZYME® is indicated, in conjunction with standard therapies, for the management of pediatric and adult patients with cystic fibrosis (CF) to improve pulmonary function. In CF patients with an FVC ≥ 40% of predicted, daily administration of PULMOZYME has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.PULMOZYME® is indicated, in conjunction with standard therapies, for the management of pediatric and adult patients with cystic fibrosis (CF) to improve pulmonary function. In CF patients with an FVC ≥ 40% of predicted, daily administration of PULMOZYME has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- dornase alfadornase alfa
- Form and strength
- SOLUTION · 1 mg / 1 mLSOLUTION · 1 mg / 1 mL
- Manufacturer / applicant
- GENENTECH, INC.GENENTECH, INC.
Inhalation solution: 2.5 mg/2.5 mL (1 mg/mL) clear, colorless solution in single-dose ampules.Inhalation solution: 2.5 mg/2.5 mL (1 mg/mL) clear, colorless solution in single-dose ampules.
Safety and clinical review
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is PULMOZYME used for?
PULMOZYME® is indicated, in conjunction with standard therapies, for the management of pediatric and adult patients with cystic fibrosis (CF) to improve pulmonary function. In CF patients with an FVC ≥ 40% of predicted, daily administration of PULMOZYME has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.PULMOZYME® is indicated, in conjunction with standard therapies, for the management of pediatric and adult patients with cystic fibrosis (CF) to improve pulmonary function. In CF patients with an FVC ≥ 40% of predicted, daily administration of PULMOZYME has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of PULMOZYME should I ask about?
SOLUTION · 1 mg / 1 mLSOLUTION · 1 mg / 1 mL
Read the primary sourceWhat determines the price of PULMOZYME?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using PULMOZYME?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.